Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Composition of immune cell subsets in peripheral blood and thyroid tissues from MNG patients. (A) The flowchart of the work. (B) t-SNE islands for CD3 + T cells, CD4 + T cells, CD8 + T cells, CD3 + CD56 + cells, CD56 + NK cells, CD19 + B cells, and CD14 + monocytes of flow cytometry data. (C) Representative immunofluorescence staining of CD4 (pink), CD8 (red), CD56 (yellow), and CD20 (green) in an MNG. DAPI staining is shown in blue. Scale bar, 50 μm (left), 10 μm (right). Percentages of T cells (D) , NK cells (E) , and CD3 + CD56 + cells (F) in MNCs in peripheral blood and thyroid tissue. (G) Ratio of CD8 + T to CD4 + T cells in peripheral blood and thyroid tissue. (H) Percentage of Treg cells in total CD4 + T cells. Percentages of memory T cells (CD45RO + CD45RA - ) in CD4 + T (I) and CD8 + T (J) cells. (D–J) The individual dot represents a patient, and data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques: Flow Cytometry, Immunofluorescence, Staining

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Memory T cells and Treg cells in thyroid tissues from MNG and PTC patients. (A) Representative FACS plots show CD45RO and CD45RA expressions on CD8 + T and CD4 + T cells. The values within solid line boxes indicate the proportions of memory T cells (CD45RO + CD45RA - ) to CD8 + T or CD4 + T cells. (B) Frequencies of memory T cells relative to CD8 + T cells are shown. (C) Frequencies of memory T cells relative to CD4 + T cells are shown. (D) Representative FACS plots show CD25 and CD127 expressions on CD4 + T cells. The values within solid line boxes indicate the proportions of Treg cells (CD25 + CD127 - ) to CD4 + T cells. (E) Frequencies of Treg cells relative to CD4 + T cells are shown. Blue means MNG, yellow means paratumor, and red means tumor. (B–E) Data presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques:

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Phenotypic characteristics of CD8 + T cells in thyroid tissues from MNG and PTC patients. (A) Flow cytometric analysis PD-1 and CD39 expression on CD8 + T cells from thyroid tissues of MNG and PTC patients. Numbers in each quadrant indicate percent cells positive for PD-1 and/or CD39 on CD8 + T cells. Below, histograms show the CD103 expression on PD-1 + CD39 - (PD-1 + , blue), PD-1 - CD39 - (DN, green), PD-1 - CD39 + (CD39 + , gray), and PD-1 + CD39 + (DP, purple) cells. Frequencies of PD-1 + CD39 + CD103 + CD8 + T (B) , PD-1 - CD39 + CD103 + CD8 + T (C) , PD-1 + CD39 + CD103 - CD8 + T (D) , and PD-1 + CD39 - CD103 + CD8 + T (E) cells in thyroid tissues of MNG and PTC patients. Data presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: mIHC-based quantification of CD8 + T-cell subsets in tissues from non-recurrent and recurrent PTC patients. Representative immunofluorescence staining of CD8 (red), CD39 (yellow), CD103 (orange), and PD-1 (cyan) in non-recurrent (A) and recurrent PTC tissues (B) . DAPI staining is shown in blue. Scale bar, 100 μm, 10 μm. Frequencies (C) and density (D) of PD-1 + CD39 + CD103 + CD8 + T cells and PD-1 + CD39 + CD103 - CD8 + T cells in non-recurrent PTC tissues (n = 23) and recurrent PTC tissues (n = 8). (Density: total PD-1 + CD39 + CD103 + CD8 + T- and PD-1 + CD39 + CD103 - CD8 + T-cell numbers divided by area of tissue per paraffin sections). Data presented as mean ± SEM. *p < 0.05; **p < 0.01.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques: Immunofluorescence, Staining

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Clinical significance of PTC-infiltrating CD8 hi T-cell subsets. This figure refers to TCGA THCA cohort (n = 195). (A) Comparison of pathological subtypes with CD8 hi T-cell subsets. (B) Comparison of gender with CD8 hi T-cell subsets. (C) The recurrence-free survival compared among eight clusters in TCGA database, including the PD-1 lo CD39 lo CD103 lo (n = 31), PD-1 lo CD39 lo CD103 hi (n = 16), PD-1 hi CD39 lo CD103 lo (n = 10), PD-1 hi CD39 lo CD103 hi (n = 41), PD-1 hi CD39 hi CD103 hi (n = 34), PD-1 hi CD39 hi CD103 lo (n = 12), PD-1 lo CD39 hi CD103 lo (n = 45), and PD-1 lo CD39 hi CD103 hi (n = 6) clusters. (D) The recurrence-free survival compared between the PD-1 hi CD39 lo CD103 hi , PD-1 hi CD39 hi CD103 lo , and PD-1 lo CD39 hi CD103 hi clusters and the other five clusters. Analyses were performed with Kaplan–Meier estimates and two-sided log-rank tests. p < 0.05 was considered significant. *p < 0.05.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques: Comparison

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Multinomial logistic regression analysis of clinical parameters associated with PD-1 lo CD39 hi CD103 hi CD8 hi T, PD-1 hi CD39 hi CD103 lo CD8 hi T, and PD-1 hi CD39 lo CD103 hi CD8 hi T cells in tumor from TCGA data.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques:

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Univariate and multivariate Cox proportional hazard models for recurrence-free survival.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques:

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Differences in immune cells and regulatory factors in CD8 hi T-cell subsets. (A) GSVA enrichment scores of the classical gene signatures for immune cells among the PD-1 hi CD39 lo CD103 hi , PD-1 hi CD39 hi CD103 lo , and PD-1 lo CD39 hi CD103 hi clusters and the other five clusters. (B) The mRNA expression of immune cell regulatory factors in the PD-1 hi CD39 lo CD103 hi , PD-1 hi CD39 hi CD103 lo , and PD-1 lo CD39 hi CD103 hi clusters compared with the other five clusters. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: Immune profiling identifies CD8 + T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer

doi: 10.3389/fimmu.2022.894919

Figure Lengend Snippet: Multinomial logistic regression analysis of immune cells associated with PD-1 hi CD39 hi CD103 lo CD8 hi T, PD-1 hi CD39 lo CD103 hi CD8 hi T, and PD-1 lo CD39 hi CD103 hi CD8 hi T cells in tumor from TCGA data.

Article Snippet: The CD8 + T-cell subsets were labeled by CD8 (C8/144B, 1:200, CST) with Opal 690, CD103 (ab224202, 1:200, Abcam) with Opal 620, PD-1 (EH33, 1:200, CST) with Opal520, and CD39 (ab223842, 1:3000, Abcam) with Opal 540.

Techniques: